Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E81.35 EPS (ttm)2.07 Insider Own0.10% Shs Outstand249.24M Perf Week-9.16%
Market Cap41.91B Forward P/E26.76 EPS next Y6.28 Insider Trans-60.58% Shs Float249.24M Perf Month-6.57%
Income536.40M PEG1.52 EPS next Q0.97 Inst Own97.10% Short Float1.38% Perf Quarter-11.74%
Sales3.05B P/S13.75 EPS this Y99.10% Inst Trans0.01% Short Ratio2.48 Perf Half Y-9.32%
Book/sh17.40 P/B9.66 EPS next Y54.56% ROA43.80% Target Price208.42 Perf Year2.94%
Cash/sh12.71 P/C13.23 EPS next 5Y53.64% ROE67.50% 52W Range144.07 - 195.81 Perf YTD1.48%
Dividend- P/FCF35.68 EPS past 5Y23.90% ROI11.20% 52W High-14.12% Beta1.64
Dividend %- Quick Ratio3.30 Sales past 5Y20.30% Gross Margin86.60% 52W Low16.72% ATR5.08
Employees2500 Current Ratio3.40 Sales Q/Q33.50% Oper. Margin20.80% RSI (14)30.87 Volatility4.01% 2.67%
OptionableYes Debt/Eq0.13 EPS Q/Q-109.60% Profit Margin68.80% Rel Volume2.30 Prev Close166.97
ShortableYes LT Debt/Eq0.13 EarningsMay 07 AMC Payout0.00% Avg Volume1.38M Price168.16
Recom1.90 SMA20-8.83% SMA50-8.94% SMA200-6.06% Volume3,176,312 Change0.71%
Apr-12-19Initiated Evercore ISI In-line
Mar-26-19Upgrade William Blair Mkt Perform → Outperform
Mar-19-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
11:02AM  5 Top Healthcare Stocks to Buy in 2019 Motley Fool
Apr-17-19 03:10PM  Dow Jones Falls As Medical Stocks Massacred, But Top Stocks Thrive In This Sector Investor's Business Daily -7.10%
10:18AM  Qualcomm's 23% one-day stock surge is a rarity for the market CNBC
07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:18PM  CRISPR Therapeutics Attempts Breakout on FDA Fast Track Investopedia
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia GlobeNewswire
Apr-15-19 07:47AM  Heres one way to tell if a company is overpaying its CEO MarketWatch
Apr-12-19 08:00AM  Vertex to Announce First-Quarter 2019 Financial Results on April 30 Business Wire
Apr-11-19 08:23AM  Has Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Got Enough Cash? Simply Wall St.
Apr-09-19 11:07AM  Why Vertex Pharmaceuticals Could Conceivably Succeed Too Well Motley Fool
09:53AM  5 Stocks in the Age of Miracles Motley Fool
09:27AM  The 10 Fastest-Growing Stocks to Invest In Right Now InvestorPlace
Apr-05-19 10:53AM  Check Out These 7 Fast-Growing Stocks to Buy Today InvestorPlace
Apr-04-19 01:38PM  Biotech, in motion: Demand for life science execs fuels game of musical chairs American City Business Journals
Apr-02-19 08:00AM  Vertex Appoints Charles Wagner as Chief Financial Officer Business Wire
Mar-31-19 09:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Mar-29-19 10:36AM  4 Small Biotech Stocks Likely to Witness More Upside in 2019 Zacks
Mar-28-19 04:35PM  As The Stock Market Rally Weakens, Here's Why You Need These Sell Rules Investor's Business Daily
08:19AM  Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Mar-27-19 11:51PM  Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy? Insider Monkey
Mar-26-19 12:11PM  Proteostasis Plunges on Weak Data From Cystic Fibrosis Study Zacks
09:04AM  Stocks Rally On Federal Reserve Shift; Dow Jones Leader In Buy Range Investor's Business Daily
Mar-25-19 04:20PM  Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable Investor's Business Daily
12:35PM  Proteostatis stock plunges on cystic fibrosis triple combo data American City Business Journals
10:42AM  Proteostasis Therapeutics's stock plunges to pace all decliners after results of CF treatment trial disappoint MarketWatch
Mar-24-19 09:00AM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Mar-21-19 06:00AM  CRISPR and Vertex- Front-Runners in Gene-Therapy MoneyShow
Mar-19-19 04:31PM  Biotech Giant Tumbles On Downgrade Amid Payer Pushback In Europe Investor's Business Daily
Mar-13-19 05:31PM  5 Biotech Stocks to Keep an Eye on in 2019 GuruFocus.com
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
09:30AM  CELG vs. VRTX: Which Stock Is the Better Value Option? Zacks
Mar-12-19 05:07AM  Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations Business Wire
Mar-11-19 01:41PM  Mass. firms riding bull market to nearly $1 trillion in gains American City Business Journals
Mar-10-19 07:11PM  Why Vertex's Dilemma Makes It the Best Biotech Stock to Buy Now Motley Fool
Mar-07-19 01:38PM  Top Research Reports for Amazon, Berkshire Hathaway & Thermo Fisher Zacks
09:31AM  Why Is Vertex (VRTX) Down 0.7% Since Last Earnings Report? Zacks
08:40AM  Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed Zacks
Mar-06-19 05:50PM  More biotech takeover targets coming, says Jefferies top analyst CNBC Videos
12:24PM  Vertex cystic fibrosis triple combo therapy succeeds in important trials Reuters
12:15PM  4 Low-Priced Stocks Under $10 for 2019 InvestorPlace
09:32AM  CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Business Wire
08:15AM  Detailed Research: Economic Perspectives on KAR Auction Services, Spectrum Brands, Vertex Pharmaceuticals, The Kraft Heinz, comScore, and Retrophin What Drives Growth in Today's Competitive Landscape GlobeNewswire
08:09AM  Vertex's cystic fibrosis therapy meets goal of late-stage studies Reuters
04:43AM  Mass. life science leaders say outgoing FDA head was an 'advocate for modernization' American City Business Journals
Mar-05-19 06:00AM  3 Hot Stocks to Buy in March Motley Fool
Mar-01-19 07:18AM  5 Top Stocks to Buy in March Motley Fool
Feb-28-19 03:53PM  5 Pharmaceutical Stocks With Big Moats and Bridges Kiplinger
Feb-27-19 04:25PM  Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates Zacks
08:21AM  3 Arguments For and Against Buying GW Pharmaceuticals Motley Fool
Feb-26-19 10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
Feb-25-19 08:00AM  CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 GlobeNewswire
12:58AM  [$$] Crispr Therapeutics treats its first human with gene editing Financial Times
Feb-24-19 02:00PM  Could Vertex Pharmaceuticals Be a Millionaire-Maker Stock? Motley Fool
Feb-22-19 08:45AM  The Zacks Analyst Blog Highlights: Nike, 3M, Vertex, PepsiCo and Verisk Zacks
08:00AM  The Top 5 Biotech Stocks Are Facing Growth Challenges Are Any Immune? Investor's Business Daily
Feb-21-19 04:01PM  Vertex Appoints Lloyd Carney to its Board of Directors Business Wire
01:59PM  Top Stock Reports for Nike, 3M & Vertex Zacks
09:44AM  The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis Zacks
Feb-20-19 10:03AM  Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More Zacks
09:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Feb-17-19 09:12AM  3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys? Motley Fool
Feb-14-19 09:04AM  Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission Business Wire
Feb-13-19 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $20.1 million of Shares GuruFocus.com
11:26AM  Have Insiders Been Selling Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares? Simply Wall St.
Feb-11-19 08:05AM  Groupon (GRPN) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-10-19 09:00AM  This Is the Best Biotech Stock on the Market Motley Fool
Feb-08-19 07:04AM  Factors Likely to Influence Cisco's (CSCO) Earnings in Q2 Zacks
05:07AM  Factors Expected to Influence Akamai's (AKAM) Q4 Earnings Zacks
Feb-07-19 03:33PM  Vertex Pharmaceuticals: New Drug, Same Great Growth Story Motley Fool
09:39AM  The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO Zacks
Feb-06-19 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $6 million of Shares GuruFocus.com
10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
10:12AM  Stocks Turn Lower, But These Top Stocks Break Out On Earnings Investor's Business Daily
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
08:10AM  Vertex Pharmaceuticals (VRTX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:28AM  Dow Jones Futures: Snap Soars, But These 4 Top Stocks Are Crossing Buy Points Investor's Business Daily
07:06AM  Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink Zacks
Feb-05-19 05:20PM  Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates Zacks
05:09PM  This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales Investor's Business Daily
04:19PM  Vertex: 4Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results Business Wire
02:30PM  Vertex Pharmaceuticals Incorporated to Host Earnings Call ACCESSWIRE
11:06AM  Vertex Earnings, Revenue beat in Q4 Investing.com
Feb-04-19 08:58AM  Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store? Zacks
08:55AM  Qorvo (QRVO) to Report Q3 Earnings: What's in the Cards? Zacks
Feb-01-19 09:48AM  6 Biotech Stocks to Watch Now Motley Fool
Jan-31-19 07:18PM  Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales? Zacks
07:35AM  Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-29-19 09:30PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
10:31AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
10:11AM  Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids Zacks
10:00AM  Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings? Zacks
Jan-28-19 09:17AM  Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene Business Wire
Jan-26-19 06:10PM  Is Vertex Pharmaceuticals a Buy? Motley Fool
Jan-25-19 10:20AM  Hot Stocks Boost USAA Aggressive Growth Investor's Business Daily
09:44AM  Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds Zacks
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG, Arbor Biotechnologies, Inc., Moderna Therapeutics, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc., as well as Janssen Pharmaceuticals, Inc. and Merck KGaA. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parini MichaelEVP, CL&AOApr 16Option Exercise111.736,375712,27939,253Apr 18 04:12 PM
Parini MichaelEVP, CL&AOApr 16Sale181.996,3751,160,16635,003Apr 18 04:12 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerApr 15Sale181.755,6241,022,14833,240Apr 17 04:30 PM
Parini MichaelEVP, CL&AOFeb 19Sale186.985,6241,051,58535,003Feb 21 04:26 PM
Silva Paul MSVP & Interim CFOFeb 19Sale186.972,812525,74717,759Feb 21 04:27 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 19Sale187.005,6241,051,71631,553Feb 21 04:21 PM
Kewalramani ReshmaEVP and CMOFeb 19Sale186.941,488278,16313,736Feb 21 04:22 PM
LEIDEN JEFFREY MCEO & PresidentFeb 19Sale186.9820,9973,926,113106,195Feb 21 04:24 PM
Silva Paul MSVP & Interim CFOFeb 11Sale180.164,215759,36720,571Feb 13 04:27 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 11Sale180.2133,0735,959,96938,864Feb 13 04:37 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale180.2232,9565,939,18837,177Feb 13 04:36 PM
Sachdev AmitEVP, CROFeb 11Sale180.0635,0956,319,21640,165Feb 13 04:40 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale180.24111,43120,083,804127,192Feb 13 04:39 PM
Silva Paul MSVP & Interim CFOFeb 06Option Exercise91.051,289117,36313,938Feb 07 04:04 PM
Silva Paul MSVP & Interim CFOFeb 06Sale193.001,289248,77712,649Feb 07 04:04 PM
Parini MichaelEVP, CL&AOFeb 04Option Exercise86.522,330201,59238,489Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Option Exercise88.494,126365,11741,443Feb 06 04:46 PM
Silva Paul MSVP & Interim CFOFeb 04Option Exercise86.5280969,99516,896Feb 06 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Option Exercise99.977,959795,65754,711Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Option Exercise88.904,097364,23548,817Feb 06 04:51 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Sale186.2018,3093,409,08236,402Feb 06 04:50 PM
Silva Paul MSVP & Interim CFOFeb 04Sale187.024,247794,27312,649Feb 06 04:49 PM
LEIDEN JEFFREY MCEO & PresidentFeb 04Sale186.3532,2506,009,682124,865Feb 06 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Sale189.194,126780,59839,113Feb 06 04:46 PM
Parini MichaelEVP, CL&AOFeb 04Sale189.192,330440,81336,159Feb 06 04:45 PM
Sachdev AmitEVP, CROFeb 04Sale186.8612,7222,377,29638,037Feb 06 04:51 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Option Exercise131.892,125280,26641,238Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Option Exercise131.892,125280,26648,877Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Option Exercise155.573,668570,63143,277Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Sale193.482,125411,14539,113Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Sale193.482,125411,14546,752Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Sale195.003,668715,26039,609Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Option Exercise155.701,223190,42140,336Jan 22 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Sale194.621,223238,02039,113Jan 22 04:07 PM
Silva Paul MSVP & Corp ControllerJan 17Option Exercise90.623,007272,48217,376Jan 18 04:18 PM
Silva Paul MSVP & Corp ControllerJan 17Sale190.623,007573,18216,087Jan 18 04:18 PM
Parini MichaelEVP, CL&AOJan 14Option Exercise90.292,125191,86641,734Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 14Sale186.712,125396,75939,609Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 04Option Exercise122.454,250520,41343,859Jan 07 04:02 PM
Parini MichaelEVP, CL&AOJan 04Sale165.904,250705,07539,609Jan 07 04:02 PM
SACHS BRUCE IDirectorDec 06Option Exercise34.2410,000342,40023,011Dec 07 04:06 PM
Silva Paul MSVP & Corp ControllerDec 03Option Exercise86.5280969,99516,896Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerDec 03Sale186.52809150,89516,087Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerNov 15Sale163.75121,96516,087Nov 19 05:52 PM
Parini MichaelEVP, CL&AONov 15Sale163.759014,73839,609Nov 19 05:47 PM
Sachdev AmitEVP, CRONov 15Sale163.75619,98946,662Nov 19 05:34 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale163.75294,74946,752Nov 19 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale163.7510016,37539,113Nov 19 05:23 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
Sachdev AmitEVP, CRONov 05Option Exercise86.521,941167,93548,603Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Option Exercise86.522,330201,59241,443Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Option Exercise103.095,803598,21151,002Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Option Exercise86.522,330201,59241,939Nov 06 04:32 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Sale172.085,803998,58046,752Nov 06 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Sale172.082,330400,94639,113Nov 06 04:11 PM
Parini MichaelEVP, CL&AONov 05Sale172.082,330400,94639,609Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Sale173.731,941337,20446,662Nov 06 04:45 PM
Sachdev AmitEVP, CRONov 02Option Exercise91.052,155196,21348,817Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Option Exercise91.051,796163,52640,909Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Option Exercise91.052,155196,21348,907Nov 05 04:52 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Sale175.361,796314,94739,113Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Sale172.862,155372,50546,662Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Sale175.362,155377,90146,752Nov 05 04:52 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86641,734Oct 16 04:29 PM
Parini MichaelEVP, CL&AOOct 12Sale177.202,125376,55039,609Oct 16 04:29 PM
Kewalramani ReshmaEVP and CMOOct 08Sale186.952,305430,9201,909Oct 09 04:50 PM
Parini MichaelEVP, CL&AOOct 04Option Exercise122.454,250520,41343,859Oct 05 05:35 PM
Parini MichaelEVP, CL&AOOct 04Sale191.584,250814,21539,609Oct 05 05:35 PM
Bhatia Sangeeta N.DirectorOct 03Option Exercise126.386,818861,6509,579Oct 05 05:28 PM
Bhatia Sangeeta N.DirectorOct 03Sale192.136,8181,309,9424,879Oct 05 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Option Exercise155.572,445380,36941,558Oct 02 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Sale194.622,445475,84639,113Oct 02 04:30 PM
Graney ThomasChief Financial OfficerOct 01Sale193.241,076207,92612,430Oct 02 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Option Exercise131.892,125280,26641,238Aug 30 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Sale181.892,125386,51639,113Aug 30 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise103.095,803598,21152,555Aug 06 05:21 PM
Sachdev AmitEVP, CROAug 03Option Exercise86.521,942168,02248,604Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59241,939Aug 07 04:46 PM
Silva Paul MSVP & Corp ControllerAug 03Option Exercise86.5280969,99516,896Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59241,443Aug 06 05:42 PM
Parini MichaelEVP, CL&AOAug 03Sale174.202,330405,88639,609Aug 07 04:46 PM
Silva Paul MSVP & Corp ControllerAug 03Sale174.20809140,92816,087Aug 06 05:38 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale174.205,8031,010,88346,752Aug 06 05:21 PM
Sachdev AmitEVP, CROAug 03Sale175.101,942340,05046,662Aug 06 06:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale174.202,330405,88639,113Aug 06 05:42 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise111.334,280476,47948,907Aug 06 05:21 PM
Sachdev AmitEVP, CROAug 02Option Exercise91.052,155196,21348,817Aug 06 06:19 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,376Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Option Exercise91.051,796163,52640,909Aug 06 05:42 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Sale174.591,796313,56439,113Aug 06 05:42 PM
Silva Paul MSVP & Corp ControllerAug 02Sale174.591,289225,04716,087Aug 06 05:38 PM
Sachdev AmitEVP, CROAug 02Sale176.732,155380,85246,662Aug 06 06:19 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale176.784,280756,61646,752Aug 06 05:21 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Option Exercise131.8923,3753,082,92962,488Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Option Exercise96.8786083,30816,947Jul 18 05:44 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM